Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$14.60 – $20.35
29% from low
Exchange
OTC Link
ADRC
Borrow rate
0.25%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.18T | $3.25T | $3.21T | $3.29T | $3.36T | $3.56T | $3.67T | $4.05T |
| Cost of revenue | $2.96T | $3.03T | $3.01T | $3.09T | $3.15T | $3.31T | $3.42T | $3.79T |
| Gross profit | $220.62B | $224.25B | $201.49B | $205.11B | $212.12B | $246.66B | $255.76B | $262.33B |
| Gross margin | 6.9% | 6.9% | 6.3% | 6.2% | 6.3% | 6.9% | 7.0% | 6.5% |
| R&D | $0 | $118.0M | $106.0M | $108.0M | $103.0M | $991.0M | $0 | $0 |
| Operating income | $49.47B | $53.11B | $38.58B | $45.63B | $48.97B | $47.33B | $55.61B | $56.39B |
| EBITDA | $77.57B | $90.36B | $53.37B | $59.96B | $63.62B | $65.31B | $95.16B | $86.28B |
| Net income | $34.36B | $37.97B | $23.93B | $29.42B | $38.81B | $41.47B | $40.28B | $45.10B |
| Net margin | 1.1% | 1.2% | 0.7% | 0.9% | 1.2% | 1.2% | 1.1% | 1.1% |
| EPS (diluted) | 145.59 | 165.33 | 106.80 | 131.41 | 179.12 | 195.83 | 193.19 | 218.90 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $3.92T | $0.00 | $0.00–$0.00 | 0 |
| 2028 | $4.02T | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
MEDIPAL HLDGS UNSP/ADR
No one on the platform currently holds MAHLY.
No tracked institution reports a position in MAHLY as of their last filing.
No one on the platform has traded MAHLY yet.
| $7.1B |
| — |
| RHCGFRyman Healthcare Limited | $1.08 | +0.00% | $1.1B | — |
| SDGCFSundrug Co.,Ltd. | $28.18 | +0.00% | $3.3B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.1× earnings vs its 0.1× historical median P/E.
Fair value ≈ $16.09 · price $16.28 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.